TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Jul 14, 2021 18:00 JST
Source:
Agilex Biolabs
Premier of South Australia Launches $1.5m Vaccine and Immunobiology State-of-the art Laboratory for APAC Clinical Trials
ADELAIDE, AUS, Jul 14, 2021 - (ACN Newswire) - Agilex Biolabs, Australia's largest and most technologically advanced regulated bioanalytical laboratory for clinical trials today announced that the Premier of South Australia the Hon Steven Marshall MP has launched its new $1.5m vaccine and immuno-biology laboratory. The facility, the most sophisticated in APAC, will attract biotechs and pharma from around the world for advanced clinical research.
Premier of South Australia the Hon Steven Marshall MP has launched Agilex Biolabs' new $1.5m vaccine and immunobiology laboratory.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Premier of South Australia, Steven Marshall launched the new facility today, thanking Agilex Biolabs for investing in the State and creating jobs in this important sector.
"South Australia is the most liveable city in the country, and the third in the world and investment such as this continues to build on this," Premier Marshall said.
"This new facility certainly puts South Australia firmly on the global map for high-tech clinical research."
"We have seen significant advances in vaccines and immunobiology in response to the COVID-19 pandemic and now the Agilex Biolabs' state-of-the-art facility offers the very latest in technology to support the further development of these new and emerging therapies targeting infections, cancer and genetic conditions."
Minister for Trade and Investment Stephen Patterson who attended the launch with the Premier said the State Government had an ambitious plan to grow SA's Health and Medical Industries sector's contribution to the state's economy.
"As a government, we're working collaboratively with industry to more than double the HMI economic contribution to SA from $2.3 billion to $5 billion by 2030.
"South Australia is open for business and at the forefront of world-leading capabilities, bio-tech precincts and an academic research ecosystem that makes it the ideal place to invest and do business."
Agilex Biolabs CEO Jason Valentine said the new laboratory focuses on new and emerging areas of therapeutic interest, including RNA vaccines, siRNA/miRNA clinical targets and gene therapy studies.
"This new facility adds digital droplet quantitative RT-PCR analysis for RNA, siRNA and miRNA clinical trials, including vaccines and gene therapy trials," he said.
"We are also installing an EliSPOT/FluoroSPOT multi-spot reader for vaccine studies to enable extrapolation of recall immune responses, which coupled with our state-of-the-art BD FACSymphony 5 laser, 20 colour flow cytometer, offers unparalleled sensitivity for immunology and vaccine trials."
This Agilex Biolabs facility adds to the recent expansion of the small molecule/novel chemical entity laboratory and implementation of the latest 6500+ Sciex LC/MS/MS platforms to enable the development and validation of the highest sensitivity assays in the region for regulated bioanalysis.
The laboratory will be completed in the next few months with international clients already booked to access the advanced technology and scientific excellence.
Agilex Biolabs has more than 130 staff which includes 85 dedicated laboratory staff, and supports client pharma and biotech companies from US, Europe and APAC.
The company offers services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.
South Australian clinical research has remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity.
Book a confidential briefing with our scientists before you start your next clinical trial.
https://calendly.com/agilexbiolabs/15min
About Agilex Biolabs
https://www.agilexbiolabs.com/
Agilex Biolabs, Australia's leading bioanalytical and toxicology laboratory, has more than 24 years' experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. It has successfully supported hundreds of preclinical and clinical trials from around the world where customers choose Australia for the streamlined regulatory process and access to the world's most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.
Agilex Biolabs has the leading certifications including OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition. The company has recently acquired TetraQ biolabs and toxicology, and also expanded its main labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the new lab video walkthrough at
https://youtu.be/WNdPGkdr9FA
.
Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).
Agilex offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
- Immunophenotyping
- Receptor occupancy
- Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
- PBMC assays and cellular mechanism of action assays
Agilex Biolabs Media Contact:
Kate Newton
Media@AgilexBiolabs.com
Source: Agilex Biolabs
Sectors: Healthcare & Pharm, Clinical Trials
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Elevating Australia's Scientific Acumen: Large Molecule Facility Doubles Size of Australia's Top Bioanalytical Laboratory
May 12 2022 15:00 JST
Agilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies - OCT Webinar
October 19 2021 15:00 JST
Agilex Biolabs Announced as Citeline Award Finalist for COVID-19 Vaccine Toxicology Preclinical Research
September 24 2021 09:00 JST
Agilex Biolabs Partners with Endpoints News for the First Webinar on Rapid Vaccine Development in Australia
August 26 2021 13:00 JST
Agilex Biolabs and Gyros Protein Technologies Partner for BioAnalysis Zone Webinar on Singlicate Analysis
May 31 2021 13:00 JST
Agilex Biolabs Partners with Endpoints News on Deconvoluting Inflammation and Immunology for Clinical Trials
May 21 2021 11:00 JST
Agilex Biolabs' Toxicology Tapped for SARS-CoV-2 Vaccine Research
May 17 2021 21:00 JST
Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results
April 30 2021 13:00 JST
Agilex Biolabs and B2S Life Sciences on Immunoassay Bioanalysis for Clinical Trials
April 29 2021 04:00 JST
Agilex Biolabs acquires leading biolab TetraQ for APAC Expansion Plans
April 07 2021 15:00 JST
More Press release >>
Latest Press Release
SPARX Group Establishes Space Frontiers Second Fund
Apr 29, 2024 18:49 JST
MHI Establishes Local Subsidiary "Mitsubishi Heavy Industries Vietnam"
Apr 29, 2024 18:00 JST
POSCO Future M and Honda Reach Basic Agreement on Collaboration for Production of Cathode Materials for Automotive Batteries in Canada
Apr 29, 2024 14:25 JST
Honda Plans to Establish Comprehensive Electric Vehicle Value Chain in Ontario, Canada
Apr 29, 2024 14:16 JST
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
More Latest Release >>